DALLAS, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Gradalis, Inc., a privately held, clinical stage biotechnology company developing a personalized immunotherapy…
Comparability of Drug Substance and Drug Product manufactured at 2,000L scale achievedMedia Release SYDNEY, AUSTRALIA, Sept. 21, 2023 (GLOBE NEWSWIRE)…
- New data from multi-dose GLP toxicology study of SNS-101 in cynomolgus monkeys further support exceptional PK and safety profile…
mTNX-1700 (mTFF2-MSA) suppresses tumor growth and increases survival rates in preclinical colorectal cancer models mTNX-1700 shows single agent activity and…
Two independent radiolabeling studies showed a 2.5- to 4.7-fold increase in tumor tissue with mIL12-FHAB, the mouse version of SON‑1010,…
The Phase 1b Clinical Trial Focuses on Assessing the Safety and Efficacy of the Two-Drug Combination in a Cancer Associated…
H3N2 HAI Response Vaccination with PDS0202 Provides broadly effective HAI antibody responses (minimum 1:40 ratio) across multiple strains of the…
Newly granted patents expand the use of the DeltEx Drug Resistant Immunotherapy (DRI) platform to encompass Chimeric Antigen Receptor T-cell…
71 Citation Laureates named by the Institute for Scientific Information have gone on to receive a Nobel Prize LONDON, Sept.…
Important step in continued protection of Poolbeg's patent familyLONDON, UK / ACCESSWIRE / September 19, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF)…